Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Fluzone in CSCC Prior to Surgery
NCT06664151Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trivalent influenza vaccine in cutaneous squamous cell carcinoma (cSCC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Mean Percent Change of CD8+ T-cells Density at 15 days. Started Nov 2024; status: recruiting.
02
Drugs
trivalent influenza vaccine
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06664151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664151.